|
1.
|
|
30 p, 7.3 MB |
Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy
/
Campillo-Marcos, Ignacio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Casado Pelaez, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mata, Caterina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mereu, Elisabetta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Valcárcel, David (Vall d'Hebron Institut d'Oncologia) ;
Molero, Antonieta (Hospital Universitari Vall d'Hebron) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tobiasson, Magnus (Karolinska Institutet (Estocolm, Suècia)) ;
Hellström-Lindberg, Eva (Karolinska Institutet (Estocolm, Suècia)) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). [...]
2024 -  10.1158/2767-9764.CRC-23-0389
Cancer Research Communications, Vol. 4 Núm. 2 (2024)
|
|
|
2.
|
|
4 p, 551.6 KB |
Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
/
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tuechler, Heinz (Boltzmann Institute for Leukaemia Research and Hematology) ;
Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ;
Raynaud, Sophie (Cote d'Azur University) ;
Cluzeau, Thomas (Cote d'Azur University) ;
Shih, Lee-Yung (Chang Gung University) ;
Tung-Liang, Chiang (Chang Gung University) ;
Ganster, Christina (University Medical Center Göttingen) ;
Shirneshan, Katayoon (University Medical Center Göttingen) ;
Haase, Detlef (University Medical Center Göttingen) ;
Mascaró, Martí (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Palomo Sanchís, Laura (Vall d'Hebron Institut d'Oncologia) ;
Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ;
Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ;
Trim, Nicola (Birmingham Women's Hospital) ;
Jeffries, Sally (Birmingham Women's Hospital) ;
Ridgway, Emma (Birmingham Women's Hospital) ;
Marconi, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ;
Martinelli, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of genomic microarrays. [...]
2023 - 10.1002/jha2.651
EJHaem, Vol. 4 (february 2023) , p. 446-449
|
|
|
3.
|
|
15 p, 1.4 MB |
Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients
/
Estrada Barreras, Natalia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ferrer-Marín, Francisca (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vélez, Patricia (Hospital Duran i Reynals (Barcelona)) ;
De la Fuente, Iris (Hospital Universitari de Girona Doctor Josep Trueta) ;
Sagüés, Miguel (Hospital Universitari de Girona Doctor Josep Trueta) ;
Cabezón, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cortés, Montserrat (Hospital de Granollers, 08402 Granollers, Spain) ;
Vallansot, Rolando Omar (Hospital Universitari Joan XXIII de Tarragona) ;
Senín-Magán, María Alicia (Hospital Duran i Reynals (Barcelona)) ;
Boque, Concepcion (Hospital Duran i Reynals (Barcelona)) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Imatinib is the most common first-line tyrosine kinase inhibitor (TKI) used to treat chronic-phase chronic myeloid leukemia (CP-CML). However, only a proportion of patients achieve major molecular response (MMR), so there is a need to find biological factors that aid the selection of the optimal therapeutic strategy (imatinib vs. [...]
2022 - 10.3390/jcm11206217
Journal of clinical medicine, Vol. 11 (october 2022)
|
|
|
4.
|
|
21 p, 2.5 MB |
Prognostic Impact of Nutritional Status After Transcatheter Edge-to-Edge Mitral Valve Repair : The MIVNUT Registry
/
Caneiro-Queija, Berenice (Instituto de Investigación Sanitaria Galicia Sur) ;
Raposeiras-Roubin, Sergio (Instituto de Investigación Sanitaria Galicia Sur) ;
Adamo, Marianna (Cardiac Catheteterization Laboratory. Cardiothoracic Department) ;
Freixa, Xavier (Hospital Clínic i Provincial de Barcelona) ;
Arzamendi, Dabit (Institut d'Investigació Biomèdica Sant Pau) ;
Benito-González, Tomás (Complejo Asistencial Universitario de León) ;
Montefusco, Antonio (Division of Cardiology. Department of Medical Science. University of Turin. Città della Salute e Della Scienza) ;
Pascual, Isaaac (Hospital Universitario Central de Asturias) ;
Nombela-Franco, Luis (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Rodes-Cabau, Josep (Laval University) ;
Shuvy, Mony (Heart Institute. Hadassah-Hebrew University Medical Center) ;
Portolés-Hernández, Antonio (Heart Institute. Hadassah-Hebrew University Medical Center) ;
Godino, Cosmo (Complejo Asistencial Universitario de León) ;
Haberman, Dan (Kaplan Medical Center) ;
Lupi, Laura (Cardiac Catheteterization Laboratory. Cardiothoracic Department) ;
Regueiro, Ander (Hospital Clínic i Provincial de Barcelona) ;
Li, Chi Hion (Institut d'Investigació Biomèdica Sant Pau) ;
Fernández-Vázquez, Felipe (Complejo Asistencial Universitario de León) ;
Frea, Simone (Division of Cardiology. Department of Medical Science. University of Turin. Città della Salute e Della Scienza) ;
Avanzas, Pablo (Hospital Universitario Central de Asturias) ;
Tirado-Conte, Gabriela (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Paradis, Jean-Michel (Cardiology Department. Quebec Heart and Lung Institute. Laval University) ;
Peretz, Alona (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Moñivas, Vanessa (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Baz, Jose A. (Instituto de Investigación Sanitaria Galicia Sur) ;
Galasso, Michele (Instituto de Investigación Sanitaria Galicia Sur) ;
Branca, Luca (Cardiac Catheteterization Laboratory. Cardiothoracic Department) ;
Sanchís, Laura (Hospital Clínic i Provincial de Barcelona) ;
Asmarats, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Garrote-Coloma, Carmen (Clinical Cardiology Unit. Faculty of Medicine. IRCCS San Raffaele Scientific Institute) ;
Angelini, Filippo (Division of Cardiology. Department of Medical Science. University of Turin. Città della Salute e Della Scienza) ;
León, Victor (Hospital Universitario Central de Asturias) ;
de Agustín, José A. (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Alperi, Alberto (Cardiology Department. Quebec Heart and Lung Institute. Laval University) ;
Beeri, Ronen (Heart Institute. Hadassah-Hebrew University Medical Center) ;
Maccagni, Gloria (Cardiac Catheteterization Laboratory. Cardiothoracic Department) ;
Sabaté, Manel (Hospital Clínic i Provincial de Barcelona) ;
Fernández-Peregrina, Estefanía (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Gualis, Javier (Complejo Asistencial Universitario de León) ;
Bocchino, Pier Paolo (Division of Cardiology. Department of Medical Science. University of Turin. Città della Salute e Della Scienza) ;
Curello, Salvatore (Cardiac Catheteterization Laboratory. Cardiothoracic Department) ;
Íñiguez-Romo, Andrés (Instituto de Investigación Sanitaria Galicia Sur) ;
Estévez-Loureiro, Rodrigo (Instituto de Investigación Sanitaria Galicia Sur)
BACKGROUND: Malnutrition is associated with poor prognosis in several cardiovascular diseases. However, its prognostic impact in patients undergoing transcatheter edge-to-edge mitral valve repair (TEER) is not well known. [...]
2022 - 10.1161/JAHA.121.023121
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol. 11 Núm. 20 (18 2022) , p. e023121
|
|
|
5.
|
|
13 p, 803.4 KB |
Prognostic role of tapse to pasp ratio in patients undergoing mitraclip procedure
/
Trejo-Velasco, Blanca (Instituto de Investigación Biomédica de Salamanca) ;
Estevez-Loureiro, Rodrigo (Hospital Álvaro Cunqueiro (Vigo)) ;
Carrasco-Chinchilla, Fernando (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ;
Fernández-Vázquez, Felipe (Hospital Universitario de León) ;
Arzamendi, Dabit (Institut d'Investigació Biomèdica Sant Pau) ;
Pan Álvarez-Ossorio, Manuel (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Pascual, Isaac (Hospital Universitario de Oviedo) ;
Nombela-Franco, Luís (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Amat-Santos, Ignacio J (Hospital Universitario de Valladolid) ;
Freixa, Xavier (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Hernández-Antolín, Rosa Ana (Hospital Universitario Ramón y Cajal (Madrid)) ;
Trillo-Nouche, Ramiro (Hospital Universitario de Santiago) ;
Ikazuriaga, L.A. (Hospital de Basurto (Bilbao, Biscaia)) ;
López-Mínguez, José Ramón (Hospital Universitario de Badajoz) ;
Cervera, Dario Sanmiguel (Hospital Universitario de Valencia) ;
Sanchis, Juan (Hospital Universitario de Valencia) ;
Diez-Gil, José Luís (Hospital Universitari i Politècnic La Fe (València)) ;
Ruiz-Quevedo, Valeriano (Hospital Universitario de Navarra) ;
Urbano-Carrillo, Cristóbal A. (Hospital Regional Universitario de Málaga) ;
Becerra-Muñoz, Víctor Manuel (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ;
Benito-González, Tomás (Hospital Universitario de León) ;
Li, Chi Hion (Institut d'Investigació Biomèdica Sant Pau) ;
Mesa, Dolores (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Avanzas, Pablo (Hospital Universitario de Oviedo) ;
Armijo, Germán (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Serrador-Frutos, Ana María (Hospital Universitario de Valladolid) ;
Sanchis, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Fernández-Golfín, Covadonga (Hospital Universitario Ramón y Cajal (Madrid)) ;
Cid-Álvarez, Belén (Hospital Universitario de Santiago) ;
Hernández-García, José María (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ;
Garrote-Coloma, Carmen (Hospital Universitario de León) ;
Fernández-Peregrina, Estefanía (Institut d'Investigació Biomèdica Sant Pau) ;
Romero, Miguel A. (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Argüero, Víctor León (Hospital Universitario de Oviedo) ;
Cruz-González, Ignacio (Hospital Universitario de Salamanca)
Background: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk patients with severe mitral regurgitation (MR) but heart failure (HF) readmissions and death remain substantial on mid-term follow-up. [...]
2021 - 10.3390/jcm10051006
Journal of clinical medicine, Vol. 10 Núm. 5 (january 2021) , p. 1-13
|
|
|
6.
|
|
13 p, 3.0 MB |
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
/
Ademà, Vera (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Walter, Wencke (Munich Leukemia Laboratory) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hutter, Stephan (Munich Leukemia Laboratory) ;
La Framboise, Thomas (Department of Genetics and Genome Sciences. Case Western Reserve University) ;
Arenillas, Leonor (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Meggendorfer, Manja (Munich Leukemia Laboratory) ;
Radivoyevitch, Tomas (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pellagatti, Andrea (Blood Cancer UK Molecular Haematology Unit. Nuffield Division of Clinical Laboratory Sciences. Radcliffe Department of Medicine. University of Oxford and Oxford BRC Haematology Theme) ;
Haferlach, Claudia (Munich Leukemia Laboratory) ;
Boultwood, Jacqueline (University of Oxford. Radcliffe Department of Medicine) ;
Kern, Wolfgang (Munich Leukemia Laboratory) ;
Visconte, Valeria (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ;
Sekeres, Mikkael (Leukemia Program. Department of Hematology and Medical Oncology. Cleveland Clinic. Cleveland Clinic Taussig Cancer Institute) ;
Barnard, John (Department of Quantitative Health Sciences. Cleveland Clinic. Lerner Research Institute) ;
Haferlach, Torsten (Munich Leukemia Laboratory) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Maciejewski, Jaroslaw (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute)
Background: Haploinsufficiency (HI) resulting from deletion of the long arm of chromosome 5 [del(5q)] and the accompanied loss of heterozygosity are likely key pathogenic factors in del(5q) myeloid neoplasia (MN) although the consequences of del(5q) have not been yet clarified. [...]
2022 - 10.1016/j.ebiom.2022.104059
EBioMedicine, Vol. 80 (june 2022) , art. 104059
|
|
|
7.
|
|
|
8.
|
|
17 p, 3.2 MB |
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
/
Liquori, Alessandro (Centro de Investigación Biomédica en Red de Cáncer) ;
Lesende, Iván (Universidade da Coruña) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Avetisyan, Gayane (Instituto de Investigación Sanitaria La Fe) ;
Ibáñez, Mariam (Centro de Investigación Biomédica en Red de Cáncer) ;
González-Romero, Elisa (Instituto de Investigación Sanitaria La Fe) ;
Boluda-Navarro, Mireia (Instituto de Investigación Sanitaria La Fe) ;
Morote-Faubel, Mireya (Instituto de Investigación Sanitaria La Fe) ;
Garcia-Ruiz, Cristian (Instituto de Investigación Sanitaria La Fe) ;
Martinez-Valiente, Cristina (Instituto de Investigación Sanitaria La Fe) ;
Santiago-Balsera, Marta (Instituto de Investigación Sanitaria La Fe) ;
Gomez-Seguí, Inés (Hospital Universitari i Politècnic La Fe (València)) ;
Sanjuan-Pla, Alejandra (Instituto de Investigación Sanitaria La Fe) ;
Sanz, Miguel A. (Instituto de Investigación Sanitaria La Fe) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ;
Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ;
Universitat Autònoma de Barcelona
Chromosomal abnormalities and somatic mutations are found in patients with myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in around 50-80% of cases. The identification of these alterations is important for the accurate diagnosis and prognostic classification of these patients. [...]
2021 - 10.3390/cancers13081947
Cancers, Vol. 13 (april 2021)
|
|
|
9.
|
|
469.5 KB |
Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes
/
Martin, Roman (University Medical Center Göttingen) ;
Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ganster, Christina (University Medical Center Göttingen) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Dierks, Sascha (University Medical Center Göttingen) ;
Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ademà, Vera (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gómez-Marzo, Paula (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
De Haro, Nuri (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Solanes, Neus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Shirneshan, Katayoon (University Medical Center Göttingen) ;
Flach, Johanna (University Medical Center Göttingen) ;
Braulke, Friederike (University Medical Center Göttingen) ;
Schanz, Julie (University Medical Center Göttingen) ;
Kominowski, Arkadiusz (University Medical Center Göttingen) ;
Stromburg, Martin (University Medical Center Göttingen) ;
Brockmann, Alina (University Medical Center Göttingen) ;
Trümper, Lorenz (University Medical Center Göttingen) ;
Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Haase, Detlef (University Medical Center Göttingen) ;
Universitat Autònoma de Barcelona
2018 - 10.1002/ajh.25089
American Journal of Hematology, Vol. 93 (april 2018) , p. E152-E154
|
|
|
10.
|
|
17 p, 2.3 MB |
Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach
/
Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Grau Cat, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rodríguez-Luaces, Marta (Hospital de Tortosa Verge de la Cinta) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster-Tormo, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological diseases. Among them, the most well characterized subtype is MDS with isolated chromosome 5q deletion (MDS del(5q)), which is the only one defined by a cytogenetic abnormality that makes these patients candidates to be treated with lenalidomide. [...]
2021 - 10.3390/cancers13040841
Cancers, Vol. 13 Núm. 4 (2021) , p. 841
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
